Bone  ||| S:0 E:5 ||| JJ
ultrasonography  ||| S:5 E:21 ||| NN
in  ||| S:21 E:24 ||| IN
kidney  ||| S:24 E:31 ||| NN
disease ||| S:31 E:38 ||| NN
:  ||| S:38 E:40 ||| :
applications  ||| S:40 E:53 ||| NNS
and  ||| S:53 E:57 ||| CC
limitations  ||| S:57 E:69 ||| NNS
Quantitative  ||| S:69 E:82 ||| JJ
ultrasound  ||| S:82 E:93 ||| NN
( ||| S:93 E:94 ||| -LRB-
QUS ||| S:94 E:97 ||| NNP
)  ||| S:97 E:99 ||| -RRB-
of  ||| S:99 E:102 ||| IN
the  ||| S:102 E:106 ||| DT
bone  ||| S:106 E:111 ||| NN
is  ||| S:111 E:114 ||| VBZ
a  ||| S:114 E:116 ||| DT
technique  ||| S:116 E:126 ||| NN
that  ||| S:126 E:131 ||| WDT
is  ||| S:131 E:134 ||| VBZ
generating  ||| S:134 E:145 ||| VBG
great  ||| S:145 E:151 ||| JJ
interest  ||| S:151 E:160 ||| NN
among  ||| S:160 E:166 ||| IN
bone  ||| S:166 E:171 ||| NN
structure  ||| S:171 E:181 ||| NN
researchers  ||| S:181 E:193 ||| NNS
because  ||| S:193 E:201 ||| IN
of  ||| S:201 E:204 ||| IN
its  ||| S:204 E:208 ||| PRP$
intrinsic  ||| S:208 E:218 ||| JJ
features ||| S:218 E:226 ||| NNS
.  ||| S:226 E:228 ||| .
Its  ||| S:228 E:232 ||| PRP$
safety  ||| S:232 E:239 ||| NN
and  ||| S:239 E:243 ||| CC
low  ||| S:243 E:247 ||| JJ
cost  ||| S:247 E:252 ||| NN
make  ||| S:252 E:257 ||| VBP
it  ||| S:257 E:260 ||| PRP
an  ||| S:260 E:263 ||| DT
ideal  ||| S:263 E:269 ||| JJ
technique  ||| S:269 E:279 ||| NN
for  ||| S:279 E:283 ||| IN
repeated  ||| S:283 E:292 ||| JJ
measurements  ||| S:292 E:305 ||| NNS
over  ||| S:305 E:310 ||| IN
time  ||| S:310 E:315 ||| NN
such  ||| S:315 E:320 ||| JJ
as  ||| S:320 E:323 ||| IN
in  ||| S:323 E:326 ||| IN
chronic  ||| S:326 E:334 ||| JJ
disease  ||| S:334 E:342 ||| NN
or  ||| S:342 E:345 ||| CC
when  ||| S:345 E:350 ||| WRB
it  ||| S:350 E:353 ||| PRP
is  ||| S:353 E:356 ||| VBZ
necessary  ||| S:356 E:366 ||| JJ
to  ||| S:366 E:369 ||| TO
monitor  ||| S:369 E:377 ||| VB
the  ||| S:377 E:381 ||| DT
effects  ||| S:381 E:389 ||| NNS
of  ||| S:389 E:392 ||| IN
prescribed  ||| S:392 E:403 ||| JJ
therapies ||| S:403 E:412 ||| NNS
.  ||| S:412 E:414 ||| .
The  ||| S:414 E:418 ||| DT
method  ||| S:418 E:425 ||| NN
was  ||| S:425 E:429 ||| VBD
developed  ||| S:429 E:439 ||| VBN
for  ||| S:439 E:443 ||| IN
the  ||| S:443 E:447 ||| DT
study  ||| S:447 E:453 ||| NN
of  ||| S:453 E:456 ||| IN
osteoporosis  ||| S:456 E:469 ||| NN
and  ||| S:469 E:473 ||| CC
the  ||| S:473 E:477 ||| DT
sites  ||| S:477 E:483 ||| NNS
of  ||| S:483 E:486 ||| IN
measurement  ||| S:486 E:498 ||| NNS
are  ||| S:498 E:502 ||| VBP
all  ||| S:502 E:506 ||| DT
peripheral ||| S:506 E:516 ||| JJ
,  ||| S:516 E:518 ||| ,
including  ||| S:518 E:528 ||| VBG
the  ||| S:528 E:532 ||| DT
distal  ||| S:532 E:539 ||| JJ
diaphyses  ||| S:539 E:549 ||| NN
and  ||| S:549 E:553 ||| CC
metaphyses  ||| S:553 E:564 ||| NN
of  ||| S:564 E:567 ||| IN
the  ||| S:567 E:571 ||| DT
phalanges ||| S:571 E:580 ||| NN
,  ||| S:580 E:582 ||| ,
calcaneus ||| S:582 E:591 ||| NN
,  ||| S:591 E:593 ||| ,
radius  ||| S:593 E:600 ||| NN
and  ||| S:600 E:604 ||| CC
tibia ||| S:604 E:609 ||| NN
.  ||| S:609 E:611 ||| .
QUS  ||| S:611 E:615 ||| NNP
parameters ||| S:615 E:625 ||| NNS
,  ||| S:625 E:627 ||| ,
however ||| S:627 E:634 ||| RB
,  ||| S:634 E:636 ||| ,
cannot  ||| S:636 E:643 ||| RB
be  ||| S:643 E:646 ||| VB
used  ||| S:646 E:651 ||| VBN
directly  ||| S:651 E:660 ||| RB
for  ||| S:660 E:664 ||| IN
the  ||| S:664 E:668 ||| DT
diagnosis  ||| S:668 E:678 ||| NN
of  ||| S:678 E:681 ||| IN
osteoporosis  ||| S:681 E:694 ||| NNS
according  ||| S:694 E:704 ||| VBG
to  ||| S:704 E:707 ||| TO
the  ||| S:707 E:711 ||| DT
WHO  ||| S:711 E:715 ||| WP
criteria ||| S:715 E:723 ||| NNS
,  ||| S:723 E:725 ||| ,
although  ||| S:725 E:734 ||| IN
many  ||| S:734 E:739 ||| JJ
authors  ||| S:739 E:747 ||| NNS
have  ||| S:747 E:752 ||| VBP
shown  ||| S:752 E:758 ||| VBN
that  ||| S:758 E:763 ||| IN
ultrasound  ||| S:763 E:774 ||| JJ
parameters ||| S:774 E:784 ||| NNS
,  ||| S:784 E:786 ||| ,
particularly  ||| S:786 E:799 ||| RB
those  ||| S:799 E:805 ||| DT
of  ||| S:805 E:808 ||| IN
calcaneal  ||| S:808 E:818 ||| JJ
QUS ||| S:818 E:821 ||| NNP
,  ||| S:821 E:823 ||| ,
can  ||| S:823 E:827 ||| MD
predict  ||| S:827 E:835 ||| VB
the  ||| S:835 E:839 ||| DT
risk  ||| S:839 E:844 ||| NN
of  ||| S:844 E:847 ||| IN
osteoporotic  ||| S:847 E:860 ||| JJ
fractures  ||| S:860 E:870 ||| NNS
independently  ||| S:870 E:884 ||| RB
of  ||| S:884 E:887 ||| IN
MBD ||| S:887 E:890 ||| NNP
.  ||| S:890 E:892 ||| .
Very  ||| S:892 E:897 ||| RB
promising  ||| S:897 E:907 ||| JJ
results  ||| S:907 E:915 ||| NNS
with  ||| S:915 E:920 ||| IN
the  ||| S:920 E:924 ||| DT
use  ||| S:924 E:928 ||| NN
of  ||| S:928 E:931 ||| IN
QUS  ||| S:931 E:935 ||| NNP
have  ||| S:935 E:940 ||| VBP
been  ||| S:940 E:945 ||| VBN
obtained  ||| S:945 E:954 ||| VBN
in  ||| S:954 E:957 ||| IN
corticosteroid-induced  ||| S:957 E:980 ||| JJ
osteoporosis ||| S:980 E:992 ||| NN
,  ||| S:992 E:994 ||| ,
rheumatoid  ||| S:994 E:1005 ||| JJ
arthritis ||| S:1005 E:1014 ||| NN
,  ||| S:1014 E:1016 ||| ,
Cushing ||| S:1016 E:1023 ||| NNP
's  ||| S:1023 E:1026 ||| POS
syndrome ||| S:1026 E:1034 ||| NN
,  ||| S:1034 E:1036 ||| ,
cystic  ||| S:1036 E:1043 ||| JJ
fibrosis ||| S:1043 E:1051 ||| NN
,  ||| S:1051 E:1053 ||| ,
osteomalacia ||| S:1053 E:1065 ||| NN
,  ||| S:1065 E:1067 ||| ,
thalassemia  ||| S:1067 E:1079 ||| NN
and  ||| S:1079 E:1083 ||| CC
osteopenia  ||| S:1083 E:1094 ||| VB
related  ||| S:1094 E:1102 ||| VBN
to  ||| S:1102 E:1105 ||| TO
parenteral  ||| S:1105 E:1116 ||| VB
nutrition ||| S:1116 E:1125 ||| NN
.  ||| S:1125 E:1127 ||| .
QUS  ||| S:1127 E:1131 ||| NNP
can  ||| S:1131 E:1135 ||| MD
also  ||| S:1135 E:1140 ||| RB
monitor  ||| S:1140 E:1148 ||| VB
the  ||| S:1148 E:1152 ||| DT
effectiveness  ||| S:1152 E:1166 ||| NN
of  ||| S:1166 E:1169 ||| IN
therapy  ||| S:1169 E:1177 ||| NN
in  ||| S:1177 E:1180 ||| IN
various  ||| S:1180 E:1188 ||| JJ
pathological  ||| S:1188 E:1201 ||| JJ
conditions ||| S:1201 E:1211 ||| NNS
.  ||| S:1211 E:1213 ||| .
In  ||| S:1213 E:1216 ||| IN
nephrology  ||| S:1216 E:1227 ||| VBG
the  ||| S:1227 E:1231 ||| DT
combined  ||| S:1231 E:1240 ||| JJ
use  ||| S:1240 E:1244 ||| NN
of  ||| S:1244 E:1247 ||| IN
phalangeal  ||| S:1247 E:1258 ||| JJ
QUS  ||| S:1258 E:1262 ||| NNP
and  ||| S:1262 E:1266 ||| CC
biochemical  ||| S:1266 E:1278 ||| JJ
markers  ||| S:1278 E:1286 ||| NN
of  ||| S:1286 E:1289 ||| IN
bone  ||| S:1289 E:1294 ||| NN
turnover  ||| S:1294 E:1303 ||| NN
allows  ||| S:1303 E:1310 ||| VBZ
adequate  ||| S:1310 E:1319 ||| JJ
follow-up  ||| S:1319 E:1329 ||| NN
of  ||| S:1329 E:1332 ||| IN
patients  ||| S:1332 E:1341 ||| NNS
on  ||| S:1341 E:1344 ||| IN
dialysis  ||| S:1344 E:1353 ||| NN
and  ||| S:1353 E:1357 ||| CC
renal  ||| S:1357 E:1363 ||| JJ
transplant  ||| S:1363 E:1374 ||| NN
recipients  ||| S:1374 E:1385 ||| NNS
with  ||| S:1385 E:1390 ||| IN
alterations  ||| S:1390 E:1402 ||| NN
or  ||| S:1402 E:1405 ||| CC
disorders  ||| S:1405 E:1415 ||| NNS
of  ||| S:1415 E:1418 ||| IN
the  ||| S:1418 E:1422 ||| DT
bone ||| S:1422 E:1426 ||| NN
.  ||| S:1426 E:1428 ||| .
